Generation of a Potential Prognostic Matrix for Papillary Thyroid Cancer that Assesses Age, Tumor Size, Transforming Growth Factor-β, and BRAFV600E Mutation

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Oncology Research and Treatment

• Publication date

  2017-09-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.1159/000477909PMID 28892804
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer : The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer

  2017cited by this paper
• Effects of Coexistent BRAFV600E and TERT Promoter Mutations on Poor Clinical Outcomes in Papillary Thyroid Cancer: A Meta-Analysis

  2017cited by this paper
• Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.

  2015cited by this paper
• Differential expression of transforming growth factor-beta in benign vs. papillary thyroid cancer nodules; a potential diagnostic tool?

  2014cited by this paper
• BRAF mutation correlates with recurrent papillary thyroid carcinoma in Chinese patients.

  2014cited by this paper
• BRAFV600E Mutation Analysis in Papillary Thyroid Carcinoma: Is it Useful for all Patients?

  2014cited by this paper
• Current thyroid cancer trends in the United States.

  2014cited by this paper
• Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.

  2013cited by this paper
• Molecular testing in thyroid cancer: BRAF mutation status and mortality.

  2013cited by this paper
• Thyroid cancer is the most common cancer in women, based on the data from population-based cancer registries, South Korea.

  2013cited by this paper
• Thyroid cancer: zealous imaging has increased detection and treatment of low risk tumours

  2013cited by this paper
• Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience.

  2013cited by this paper
• BRAFV600E Mutation is Associated with Tumor Aggressiveness in Papillary Thyroid Cancer

  2012cited by this paper
• BRAF Mutation in Papillary Thyroid Cancer and Its Value in Tailoring Initial Treatment: A Systematic Review and Meta-Analysis

  2012cited by this paper
• pROC: an open-source package for R and S+ to analyze and compare ROC curves

  2011cited by this paper
• Gender is an Age-Specific Effect Modifier for Papillary Cancers of the Thyroid Gland

  2009cited by this paper
• International patterns and trends in thyroid cancer incidence, 1973–2002

  2009cited by this paper
• 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer

  2009cited by this paper
• The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.

  2009cited by this paper
• Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer

  2009cited by this paper
• The BRAF V600E Oncogene Induces Transforming Growth Factor β Secretion Leading to Sodium Iodide Symporter Repression and Increased Malignancy in Thyroid Cancer

  2009cited by this paper
• Association of the T1799A BRAF mutation with tumor extrathyroidal invasion, higher peripheral platelet counts, and over-expression of platelet-derived growth factor-B in papillary thyroid cancer.

  2008cited by this paper
• Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer.

  2007cited by this paper
• Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion

  2007cited by this paper
• Actions of TGF-β as tumor suppressor and pro-metastatic factor in human cancer

  2007cited by this paper
• The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane.

  2006cited by this paper
• BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.

  2005cited by this paper
• The Functional Interaction between the Paired Domain Transcription Factor Pax8 and Smad3 Is Involved in Transforming Growth Factor-β Repression of the Sodium/Iodide Symporter Gene*

  2004cited by this paper
• Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population.

  2004cited by this paper
• TGF-β-induced apoptosis in human thyrocytes is mediated by p27kip1 reduction and is overridden in neoplastic thyrocytes by NF-κB activation

  2003cited by this paper
• TGF-beta-induced apoptosis in human thyrocytes is mediated by p27kip1 reduction and is overridden in neoplastic thyrocytes by NF-kappaB activation.

  2003cited by this paper
• BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas.

  2003cited by this paper
• Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers.

  2003cited by this paper
• Mutations of the BRAF gene in human cancer

  2002cited by this paper
• Expression of Transforming Growth Factor β1, β2, and β3 in Multinodular Goiters and Differentiated Thyroid Carcinomas: A Comparative Study

  1999cited by this paper
• Expression of transforming growth factor beta1, beta2, and beta3 in multinodular goiters and differentiated thyroid carcinomas: a comparative study.

  1999cited by this paper
• Transforming growth factor beta regulates thyroid growth. Role in the pathogenesis of nontoxic goiter.

  1989cited by this paper

• TGF-β, to target or not to target; to prevent thyroid cancer progression?

  2022cites this paper
• Predictive Value of Clinical and Pathological Characteristics for Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma: A 16-year Retrospective Study

  2022cites this paper
• The role of BRAF V600E mutation in post-surgical 131I therapy in papillary thyroid carcinoma. A study based on SPECT-CT uptake analysis.

  2021cites this paper